Rare Cancer News & Clinical Trials » Trial

Trial - Cholangiocarcinoma (100 unread)

1 2 3

Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma

Posted: November 24th, 2023, 3:00am GMT

Conditions: Liver Cancer
Interventions: Other: phenotyping
Sponsors: Inserm U955
Recruiting
Liver Transplantation in Intrahepatic Cholangiocarcinoma

Posted: November 20th, 2023, 3:00am GMT

Conditions: Locally Advanced Non-metastatic Intrahepatic Cholangiocarcinoma; Determine Efficacy of Liver Transplantation After Neoadjuvant Systemic Therapy in Patients With Locally Advanced Non-metastatic Intrahepatic Cholangiocarcinoma
Interventions: Procedure: Liver Transplant
Sponsors: Rutgers, The State University of New Jersey
Not yet recruiting
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Posted: November 16th, 2023, 3:00am GMT

Conditions: Carcinoma; Intrahepatic Cholangiocarcinoma; Gallbladder Cancer; Surufatinib; Angiogenesis Inhibitors; Tislelizumab; Antineoplastic Agents, Immunological; Immunotherapy
Interventions: Drug: HAIC; Drug: Surufatinib; Drug: Tislelizumab
Sponsors: Wuhan Union Hospital, China
Not yet recruiting
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors

Posted: November 10th, 2023, 3:00am GMT

Conditions: Gastric Cancer; Colon Cancer; Rectal Cancer; Breast Cancer; Lung Cancer; Esophagus Cancer; Cholangiocarcinoma; Pancreas Cancer
Interventions: Biological: CEA-targeted CAR-T cells; Biological: CEA-targeted CAR-T cells
Sponsors: Chongqing Precision Biotech Co., Ltd; First Affiliated Hospital of Wannan Medical College
Recruiting
LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA)

Posted: November 9th, 2023, 3:00am GMT

Conditions: Perihilar Cholangiocarcinoma
Interventions: Procedure: Liver transplantation
Sponsors: Azienda Sanitaria Ospedaliera; Istituto Oncologico Veneto IRCCS
Not yet recruiting
A Single-center, Prospective Cohort Study on the Differentiation of Benign and Malignant Bile Duct Stenosis Based on Bile and Peripheral Blood cfDNA Methylation Profiles

Posted: November 3rd, 2023, 2:00am GMT

Conditions: Bile Duct Neoplasms; Jaundice, Obstructive; Bile Duct Diseases
Interventions: Diagnostic Test: cfDNA methylation detection
Sponsors: Air Force Military Medical University, China
Recruiting
A Study of Rilvegostomig Plus Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection

Posted: October 31st, 2023, 2:00am GMT

Conditions: Biliary Tract Cancer
Interventions: Drug: Rilvegostomig; Drug: Placebo; Drug: Capecitabine; Drug: Gemcitabine/Cisplatin; Drug: S-1 [Tegafur/Oteracil/gimeracil]
Sponsors: AstraZeneca
Not yet recruiting
Endoscopic Scissors Cutting Nasobiliary Duct VS Bilateral Plastic Stent

Posted: October 30th, 2023, 2:00am GMT

Conditions: Cholangiocarcinoma, Hilar; Biliary Stricture; Hilar Cholangiocarcinoma; Klatskin Tumor; Biliary Disease; Bile Duct Diseases; Bile Duct Stenosis
Interventions: Device: Endoscopic nasobiliary duct cutting; Device: Bilateral plastic stent
Sponsors: First People's Hospital of Hangzhou
Recruiting
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

Posted: October 26th, 2023, 2:00am GMT

Conditions: Esophageal Cancer; Small Bowel Cancer; Gastroesophageal-junction Cancer; Gastric Cancer; Colorectal Cancer; Appendiceal Cancer; Biliary Cancer; Gall Bladder Cancer; Intrahepatic Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma; Oligoprogressive
Interventions: Device: Ablative local therapy
Sponsors: University of California, Davis; National Cancer Institute (NCI)
Recruiting
LIver Transplantation for Non-Resectable Intrahepatic CholAngiocarcinoma

Posted: October 24th, 2023, 2:00am GMT

Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Procedure: Liver transplantation
Sponsors: Azienda Sanitaria Ospedaliera; Istituto Oncologico Veneto IRCCS
Not yet recruiting
Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma

Posted: October 20th, 2023, 2:00am GMT

Conditions: Bile Duct Adenocarcinoma
Interventions: Drug: surufatinib plus cadonilimab
Sponsors: Zhejiang Cancer Hospital
Recruiting
A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors

Posted: October 13th, 2023, 2:00am GMT

Conditions: Advanced Pancreatic Cancer and Cholangiocarcinoma
Interventions: Drug: PRRT with 177Lu-EB-FAPI
Sponsors: Zhejiang University
Recruiting
A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Posted: October 13th, 2023, 2:00am GMT

Conditions: Cholangiocarcinoma Non-resectable; Cholangiocarcinoma Metastatic
Interventions: Drug: Ivosidenib
Sponsors: Servier
Not yet recruiting
Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary Carcinoma

Posted: October 10th, 2023, 2:00am GMT

Conditions: Ampullary Cancer; Bile Duct Cancer; Pancreas Cancer; Duodenum Cancer
Interventions: Procedure: Modified Blumgart Anastomosis in LPD; Procedure: conventional Blumgart anastomosis in LPD
Sponsors: Affiliated Hospital of Guangdong Medical University
Enrolling by invitation
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced, Unresectable Intrahepatic Cholangiocarcinoma

Posted: September 28th, 2023, 2:00am GMT

Conditions: Locally Advanced Intrahepatic Cholangiocarcinoma; Oligometastatic Intrahepatic Cholangiocarcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Procedure: Angiography; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Durvalumab; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Biological: Tremelimumab; Procedure: Yttrium-90 Microsphere Radioembolization
Sponsors: Mayo Clinic
Not yet recruiting
Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor

Posted: September 27th, 2023, 2:00am GMT

Conditions: Cholangiocarcinoma Metastatic
Interventions: Drug: TT-00420 (tinengotinib)
Sponsors: TransThera Sciences (Nanjing), Inc.
Not yet recruiting
Durvalumab With Gemcitabine and Cisplatin for the Treatment of High Risk Resectable Liver Cancer Before Surgery

Posted: September 22nd, 2023, 2:00pm GMT

Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Cisplatin; Procedure: Computed Tomography; Biological: Durvalumab; Drug: Gemcitabine; Procedure: Magnetic Resonance Imaging; Procedure: Resection
Sponsors: National Cancer Institute (NCI)
Not yet recruiting
Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy

Posted: September 21st, 2023, 2:00pm GMT

Conditions: Biliary Tract Tumor; Cholangiocarcinoma
Interventions: Other: Blood samples, tumor biopsy specimens will be collected
Sponsors: Zhejiang Cancer Hospital
Recruiting
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers

Posted: September 21st, 2023, 2:00pm GMT

Conditions: Biliary Tract Carcinoma; Cholangiocarcinoma; Bile Duct Cancer
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Zimberelimab; Drug: Quemliclustat
Sponsors: Nataliya Uboha; Arcus Biosciences, Inc.; Gilead Sciences; University of Wisconsin, Madison
Not yet recruiting
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

Posted: September 21st, 2023, 2:00pm GMT

Conditions: Colorectal Cancer; Esophagus Cancer; Gastric Cancer; Pancreas Cancer; Non-small Cell Lung Cancer; Breast Cancer; Bile Duct Cancer
Interventions: Biological: CEA-targeted CAR-T cells
Sponsors: Chongqing Precision Biotech Co., Ltd; Zhejiang University
Recruiting
CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Posted: September 14th, 2023, 2:00pm GMT

Conditions: Biliary Tract Cancer; Cholangiocarcinoma
Interventions: Drug: Gemcitabine; Drug: Nab paclitaxel; Drug: Cisplatin; Procedure: Curative Surgery; Drug: Capecitabine
Sponsors: Gruppo Oncologico del Nord-Ovest
Recruiting
Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC

Posted: September 12th, 2023, 2:00pm GMT

Conditions: Combined Hepatocellular Cholangiocarcinoma
Interventions: Drug: gemcitabine ,oxaliplatin,anlotinib,Sintilimab
Sponsors: Sichuan University
Not yet recruiting
A Prospective, Observational Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)

Posted: September 8th, 2023, 2:00pm GMT

Conditions: Solid Tumor; Advanced Solid Tumor; Locally Advanced Solid Tumor; Colon Rectal Cancer; Gastric Cancer; Pancreatic Cancer; Bile Duct Cancer; Hepatocarcinoma; Breast Cancer; Ovarian Cancer; Endometrial Cancer; Cervical Cancer; Vulva Cancer; Melanoma
Sponsors: Centro di Riferimento Oncologico - Aviano
Recruiting
Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma

Posted: August 30th, 2023, 2:00pm GMT

Conditions: Borderline Resectable Carcinoma; Biliary Tract Cancer
Interventions: Drug: Durvalumab; Drug: Tremelimumab; Drug: Gemcitabine; Drug: Cisplatin; Procedure: Surgical Resection
Sponsors: Georgetown University; AstraZeneca
Not yet recruiting
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors

Posted: August 25th, 2023, 2:00pm GMT

Conditions: Gastric Cancer; Colon Cancer; Pancreas Cancer; Esophagus Cancer; Cholangiocarcinoma; Lung Cancer; Breast Cancer
Interventions: Biological: CEA CAR-T cells; Biological: CEA CAR-T cells
Sponsors: Chongqing Precision Biotech Co., Ltd; The First Affiliated Hospital of Nanchang University
Recruiting
Diagnostic Efficacy of EUS-FNA/B Versus ERCP With or Without POCS-TB in Patients With Suspected Hilar Cholangiocarcinoma

Posted: August 15th, 2023, 2:00pm GMT

Conditions: Klatskin Tumor; Cholangiocarcinoma; Biopsy, Fine-Needle; Endoscopic Retrograde Cholangiopancreatography
Interventions: Diagnostic Test: The sampling method selected in patients with suspected hilar cholangiocarcinoma
Sponsors: Qilu Hospital of Shandong University; First Affiliated Hospital, Sun Yat-Sen University; First Affiliated Hospital of Guangxi Medical University; LanZhou University; Sir Run Run Shaw Hospital; Wuhan Union Hospital, China
Recruiting
IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors

Posted: August 14th, 2023, 2:00pm GMT

Condition: HER2 Gene Mutation
Interventions: Combination Product: Injection of IAH0968+Gemcitabine+Cisplatin; Combination Product: Gemcitabine+Cisplatin
Sponsor: SUNHO（China）BioPharmaceutical CO., Ltd.
Recruiting
Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer

Posted: August 7th, 2023, 2:00pm GMT

Condition: Cholangiocarcinoma Non-resectable
Interventions: Drug: Candonilimab; Drug: Cisplatin; Drug: Gemcitabine
Sponsor: West China Hospital
Recruiting
IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors

Posted: August 2nd, 2023, 2:00pm GMT

Condition: Advanced Solid Tumors
Intervention: Drug: IMM2510
Sponsors: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.; Zhejiang Cancer Hospital; Fudan University
Recruiting
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

Posted: August 1st, 2023, 2:00pm GMT

Condition: Cholangiocarcinoma
Interventions: Drug: Pembrolizumab; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: M.D. Anderson Cancer Center
Not yet recruiting
[68Ga]Ga-FAPI-46 Positron Emission Tomography (PET) Scan to Improve the Imaging of Pancreatic and Bile Duct Cancer

Posted: July 24th, 2023, 2:00pm GMT

Conditions: Pancreatic Cancer; Cholangiocarcinoma
Intervention: Diagnostic Test: [68Ga]Ga-FAPI-46 PET/CT
Sponsors: Amsterdam UMC, location VUmc; Dutch Cancer Society; Leiden University Medical Center
Recruiting
Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2

Posted: July 24th, 2023, 2:00pm GMT

Conditions: Metastatic Malignant Neoplasm
Interventions: Drug: NPX267
Sponsors: NextPoint Therapeutics, Inc.
Recruiting
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Posted: July 17th, 2023, 2:00pm GMT

Conditions: Cholangiocarcinoma
Interventions: Drug: Tinengotinib 8 mg; Drug: Tinengotinib 10 mg; Drug: Physician's Choice
Sponsors: TransThera Sciences (Nanjing), Inc.
Not yet recruiting
HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study

Posted: July 5th, 2023, 2:00am GMT

Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: HMPL-453; Drug: Rabeprazole
Sponsors: Hutchmed
Completed
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

Posted: June 27th, 2023, 2:00pm GMT

Conditions: IDH1-mutant Cholangiocarcinoma
Interventions: Drug: Ivosidenib; Drug: Recommended Combination Dose (RCD) of ivosidenib; Drug: Nivolumab; Drug: Ipilimumab
Sponsors: Servier Bio-Innovation LLC; Institut de Recherches Internationales Servier
Recruiting
Senior Adult Hepatobiliary Prehab Study

Posted: June 27th, 2023, 2:00pm GMT

Conditions: Hepatobiliary Cancer; Cholangiocarcinoma; Liver Metastases
Interventions: Behavioral: Resistance Training; Behavioral: Aerobic Training
Sponsors: H. Lee Moffitt Cancer Center and Research Institute
Recruiting
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Posted: June 22nd, 2023, 2:00pm GMT

Conditions: Carcinoma; Intrahepatic Cholangiocarcinoma; Digestive System Neoplasms; PD-1 Inhibitor; First-line Treatment
Interventions: Drug: Pemigatinib; Drug: PD-1 Inhibitors
Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; First Affiliated Hospital of Jinan University; Shenzhen University General Hospital
Recruiting
Combined Treatment of Treated Bile Duct Cancer

Posted: June 22nd, 2023, 2:00pm GMT

Condition: Bile Duct Cancer
Intervention: Drug: envolizumab , sovalteinib
Sponsor: Zhejiang Cancer Hospital
Not yet recruiting
The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases

Posted: June 9th, 2023, 2:00pm GMT

Conditions: Biliary Tract Diseases; Gallbladder Cancer; Extrahepatic Bile Duct Cancer; Intrahepatic Cholangiocarcinoma; Biliary Tract Neoplasms; Gall Stone
Intervention: Other: no interventions
Sponsor: RenJi Hospital
Not yet recruiting
Phase 3b Study of Ivosidenib for Patients With Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

Posted: May 25th, 2023, 2:00pm GMT

Conditions: Cholangiocarcinoma
Interventions: Drug: Ivosidenib Oral Tablet
Sponsors: Servier Affaires Médicales
Recruiting
Endoscopic Drainage of Presumed Resectable pCCA Using an Intrahepatic Plastic Stent With Retrieval String

Posted: May 25th, 2023, 2:00pm GMT

Condition: Perihilar Cholangiocarcinoma
Intervention: Device: Intrahepatic biliary stent with retrieval string
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma

Posted: May 24th, 2023, 2:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Drug: GNS561 + Trametinib
Sponsor: Genfit
Not yet recruiting
Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer

Posted: May 24th, 2023, 2:00pm GMT

Conditions: Advanced Solid Tumor; Metastatic Solid Tumor; Lung Cancer; Colorectal Cancer; Pancreatic Cancer; Cholangiocarcinoma; Head and Neck Cancer; Non Small Cell Lung Cancer
Interventions: Biological: WM-A1-3389; Biological: Pembrolizumab
Sponsors: Wellmarker Bio; Merck Sharp & Dohme LLC
Not yet recruiting
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

Posted: May 15th, 2023, 2:00pm GMT

Conditions: Melanoma; Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; High Grade Serous Adenocarcinoma of Ovary; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Endometrial Cancer; Cervical Cancer; Renal Cell Carcinoma; Bladder Cancer; Esophageal Cancer; Gastric Cancer; Gastroesophageal-junction Cancer; Colorectal Cancer; Anal Cancer; Hepatocellular Carcinoma; Bile Duct Cancer
Interventions: Drug: AI-061
Sponsors: OncoC4, Inc.; OncoC4 AU Pty Ltd; Avance Clinical
Recruiting
A Phase I/II Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Posted: May 9th, 2023, 2:00pm GMT

Conditions: Biliary Cancer; Bile Duct Cancer; Cancer of the Bile Duct
Interventions: Drug: oxaliplatin; Drug: capecitabine; Biological: Keytruda; Biological: CDX-1140
Sponsors: National Cancer Institute (NCI)
Not yet recruiting
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Posted: May 8th, 2023, 2:00pm GMT

Conditions: Breast Cancer Metastatic; Pancreatic Cancer; NSCLC, Metastatic; Synovial Sarcoma; Colon Cancer; Metastatic Colon Cancer; Melanoma Recurrent; Metastatic Skin Cancer; Melanoma Stage IV; Triple Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Cholangiocarcinoma; Ovarian Cancer; Metastatic Melanoma; Hepatocellular Carcinoma
Interventions: Drug: ST316
Sponsors: Sapience Therapeutics
Recruiting
Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)

Posted: April 28th, 2023, 2:00pm GMT

Condition: Advanced Intrahepatic Cholangiocarcinoma
Interventions: Procedure: Cryoablation; Drug: Sintilimab; Drug: Lenvatinib
Sponsor: Fudan University
Recruiting
Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

Posted: April 21st, 2023, 2:00pm GMT

Conditions: Advanced Cholangiocarcinoma
Interventions: Drug: Lenvatinib, tislelizumab, gemcitabine and cisplatin; Drug: Gemcitabine and cisplatin
Sponsors: Second Affiliated Hospital, School of Medicine, Zhejiang University; The First Affiliated Hospital of Zhengzhou University; The Affiliated Tumor Hospital of Xinjiang Medical University
Recruiting
IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor

Posted: April 17th, 2023, 2:00pm GMT

Conditions: Cholangiocarcinoma With IDH1 Mutation; Solid Tumors With IDH1 Mutation
Intervention: Drug: AB-218 capsule
Sponsor: AnHeart Therapeutics Inc.
Not yet recruiting
IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

Posted: April 10th, 2023, 2:00pm GMT

Conditions: Advanced Solid Tumor; Advanced Lung Cancer; Advanced Gastric Carcinoma; Advanced Cholangiocarcinoma
Intervention: Drug: IMM2902
Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Recruiting
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

Posted: March 30th, 2023, 2:00pm GMT

Conditions: Advanced Cholangiocarcinoma; Advanced Hepatocellular Carcinoma; Advanced Malignant Solid Neoplasm; Metastatic Malignant Neoplasm in the Liver; Refractory Malignant Solid Neoplasm; Stage III Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Drug: RNA Transcription Modulator AU-409
Sponsors: University of Southern California; National Cancer Institute (NCI); Auransa, Inc.
Recruiting
A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients With Advanced Malignancies

Posted: March 29th, 2023, 2:00pm GMT

Conditions: Non-small Cell Lung Cancer; Gastric Cancer; Head and Neck Cancer; Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Bladder Urothelial Carcinoma; Colorectal Cancer; Esophageal Cancer; Hepatic Cancer; Renal Cell Carcinoma; Cholangiocarcinoma; Pancreatic Cancer; Other Solid Tumors
Interventions: Drug: CDX-585
Sponsors: Celldex Therapeutics
Recruiting
Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC

Posted: March 23rd, 2023, 2:00am GMT

Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cadonilimab+Gem/Cis
Sponsors: Shen Feng
Active, not recruiting
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

Posted: March 16th, 2023, 2:00pm GMT

Conditions: Biliary Tract Cancer
Interventions: Biological: Durvalumab; Drug: Gemcitabine monotherapy; Drug: Gemcitabine + cisplatin; Drug: Gemcitabine + oxaliplatin; Drug: Gemcitabine + carboplatin; Drug: Gemcitabine + cisplatin + S-1; Drug: Gemcitabine + S-1; Drug: Gemcitabine + cisplatin + albumin-bound paclitaxel
Sponsors: AstraZeneca
Recruiting
Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor

Posted: March 9th, 2023, 3:00pm GMT

Condition: Malignancy
Intervention: Drug: Al18F-PSMA-BCH PET/CT
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recruiting
First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)

Posted: March 1st, 2023, 3:00pm GMT

Condition: HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer
Intervention: Drug: Trastuzumab+Nivolumab+Gemcitabine+Cisplatin
Sponsor: Yonsei University
Not yet recruiting
A-LiNK: Improving Outcomes in Autoimmune Liver Disease

Posted: March 1st, 2023, 3:00pm GMT

Conditions: Autoimmune Hepatitis; Primary Sclerosing Cholangitis
Intervention: Other: No interventions
Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting
ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospective Trial.

Posted: February 24th, 2023, 3:00pm GMT

Condition: Biliary Tract Cancer
Intervention: Procedure: No intervention
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Recruiting
Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Posted: February 21st, 2023, 3:00pm GMT

Conditions: Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Camrelizumab; Drug: Gemcitabine Injection; Drug: Cisplatin injection; Drug: Cisplatin-Eluting Beads; Procedure: D-TACE
Sponsors: Hua Li
Recruiting
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Posted: February 17th, 2023, 3:00pm GMT

Conditions: Locally Advanced Solid Tumor
Interventions: Drug: TNG462
Sponsors: Tango Therapeutics, Inc.
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Posted: February 14th, 2023, 3:00pm GMT

Conditions: Advanced Cholangiocarcinoma; FGFR2 Fusions; Gene Rearrangement
Interventions: Drug: TAS-120
Sponsors: Taiho Oncology, Inc.
Recruiting
Domvanalimab and Zimberelimab in Advanced Liver Cancers

Posted: February 13th, 2023, 3:00pm GMT

Conditions: Hepatobiliary Cancer; Liver Cancer; Cholangiocarcinoma; Hepatocellular Carcinoma
Interventions: Drug: Zimberelimab; Drug: Domvanalimab
Sponsors: University of Texas Southwestern Medical Center; Arcus Biosciences, Inc.; Cancer Prevention Research Institute of Texas
Recruiting
Study on the Accuracy of Proteomics in Evaluating Lymph Node Metastasis Status in Cholangiocarcinoma Patients

Posted: February 10th, 2023, 3:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Diagnostic Test: No interventions.
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting
FGF19 in Obstructive Cholestasis: "Unveil the Signal"

Posted: February 8th, 2023, 3:00pm GMT

Conditions: Cholestasis; Icterus; Cholangiocarcinoma; Pancreatic Neoplasms; Liver Metastasis Colon Cancer
Intervention: Other: Biospecimen sampling
Sponsors: Nicole Hildebrand; RWTH Aachen University
Recruiting
Liver Embolization Approaches for Tumor Management

Posted: February 6th, 2023, 3:00pm GMT

Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Metastatic Colon Cancer; Metastatic Cancer; Metastatic Gastric Cancer; Primary Liver Cancer; Metastatic Pancreatic Cancer
Intervention: Procedure: Embolization
Sponsor: IRCCS San Raffaele
Recruiting
Looking At Bile Duct Cancer Patient Experience Patterns in Medical Trials

Posted: January 31st, 2023, 3:00pm GMT

Condition: Bile Duct Cancer
Intervention:
Sponsor: Power Life Sciences Inc.
Not yet recruiting
Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards

Posted: January 12th, 2023, 3:00pm GMT

Conditions: Hepatocellular Carcinoma; Fibrolamellar Hepatocellular Carcinoma; Cholangiocarcinoma, Perihilar; Intrahepatic Cholangiocarcinoma; Metastasis to Liver; Gallbladder Carcinoma
Intervention: Other: ADBoard
Sponsors: Charite University, Berlin, Germany; German Research Center for Artificial Intelligence
Not yet recruiting
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma

Posted: January 10th, 2023, 3:00pm GMT

Conditions: Hilar Cholangiocarcinoma; Intrahepatic Cholangiocarcinoma; Common Bile Duct Neoplasms; Cholangiocarcinoma; Adenocarcinoma
Interventions: Procedure: Endoscopic Ultrasound registration
Sponsors: Erasmus Medical Center
Recruiting
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Posted: December 19th, 2022, 3:00pm GMT

Conditions: Bile Duct Cancer; Cholangiocarcinoma; Cholangiocarcinoma Non-resectable; Cholangiocarcinoma Metastatic; Metastatic Intrahepatic Cholangiocarcinoma
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Durvalumab; Radiation: Yttrium-90
Sponsors: Beth Israel Deaconess Medical Center; AstraZeneca; Sirtex Medical; Dana-Farber Cancer Institute
Recruiting
Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers

Posted: December 8th, 2022, 3:00pm GMT

Conditions: Gastrointestinal Cancers; Cholangiocarcinoma; Gastric Cancer; Colorectal Cancer; Pancreatic Ductal Adenocarcinoma; Hepatocellular Carcinoma
Interventions: Drug: [18F]FAPI-74 PET/CT
Sponsors: SOFIE
Recruiting
Personalized Medicine for Advanced Biliary Cancer Patients

Posted: November 14th, 2022, 3:00pm GMT

Conditions: Biliary Tract Neoplasms
Interventions: Drug: Futibatinib; Drug: Ivosidenib; Drug: Zanidatamab; Drug: Trastuzumab; Drug: Neratinib; Drug: Encorafenib; Drug: Binimetinib; Drug: Niraparib; Drug: Cisplatin; Drug: Gemcitabine
Sponsors: UNICANCER; Cancer Research UK & UCL Cancer Trials Centre; Belgian Group of Digestive Oncology; National Cancer Institute, France; Cancer Research UK; Taiho Oncology, Inc.; Servier; Zymeworks Inc.; Accord Healthcare, Inc.; Pierre Fabre Medicament; GlaxoSmithKline Research & Development Limited
Not yet recruiting
Screening Single-operator Cholangioscopy for Neoplastic Bile Duct Lesions

Posted: November 1st, 2022, 2:00am GMT

Conditions: Cholangiocarcinoma; Bile Duct Neoplasms
Interventions: Procedure: Single-operator cholangioscopy
Sponsors: Soonchunhyang University Hospital
Recruiting
EUS-guided Choledochoduodenostomy for Primary Drainage of Malignant Distal Biliary Obstruction

Posted: October 26th, 2022, 2:00pm GMT

Conditions: Biliary Obstruction; Pancreas Neoplasm; Distal Cholangiocarcinoma
Intervention: Device: EUS-CDS
Sponsors: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); VU University of Amsterdam
Recruiting
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Posted: October 6th, 2022, 2:00pm GMT

Conditions: Ovarian Cancer; Cholangiocarcinoma Recurrent; Mesothelioma, Malignant
Interventions: Biological: SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
Sponsors: Verismo Therapeutics
Recruiting
Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements

Posted: October 4th, 2022, 2:00pm GMT

Conditions: Intrahepatic Cholangiocarcinoma; FGFR2 Gene Mutation; FGFR2 Gene Rearrangement; FGFR2 Gene Translocation
Intervention: Drug: Pemigatinib
Sponsors: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Incyte Biosciences International Sàrl
Recruiting
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Posted: October 3rd, 2022, 2:00pm GMT

Conditions: Cervical Cancer; Colorectal Cancer; Esophageal Cancer; Gastric Cancer; Glioblastoma Multiforme; Cholangiocarcinoma; Hepatocellular Carcinoma; Head and Neck Squamous Cell Carcinoma; Nasopharyngeal Carcinoma; Non Small Cell Lung Cancer; Small Cell Lung Cancer; Epithelial Ovarian Cancer; Pancreatic Ductal Adenocarcinoma; Soft Tissue Sarcoma
Intervention: Drug: 89Zr-DFO-girentuximab
Sponsor: Telix International Pty Ltd
Recruiting
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Posted: October 3rd, 2022, 2:00pm GMT

Conditions: Recurrent Biliary Tract Carcinoma; Recurrent Distal Bile Duct Adenocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Hilar Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Hilar Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Biliary Tract Carcinoma; Unresectable Distal Bile Duct Adenocarcinoma; Unresectable Gallbladder Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Binimetinib; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Bone Scan; Procedure: Computed Tomography; Procedure: Echocardiography; Drug: Fluorouracil; Drug: Leucovorin Calcium; Procedure: Magnetic Resonance Imaging; Procedure: Multigated Acquisition Scan; Drug: Oxaliplatin
Sponsors: National Cancer Institute (NCI)
Recruiting
Endoscopy and Radiology-guided Ablation for Inoperable Cholangiocarcinoma

Posted: October 3rd, 2022, 2:00am GMT

Conditions: Perihilar Cholangiocarcinoma
Interventions: Procedure: Endoluminal radiofrequency ablation; Procedure: Endoscopic biliary stenting
Sponsors: Clinical Hospital Colentina; Carol Davila University of Medicine and Pharmacy; Universitatea din Bucuresti
Recruiting
GOT Applied as Neoadjuvant Regimen for Patients of Resectable ICC With High-risk Factors of Recurrence

Posted: September 28th, 2022, 2:00pm GMT

Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Tislelizumab combined with GEMOX (GOT) regimen
Sponsors: Zhejiang Cancer Hospital
Recruiting
Treatment of Non-resectable Bile Duct Cancer With Radiofrequency Ablation or Photodynamic Therapy

Posted: September 22nd, 2022, 2:00pm GMT

Condition: Hilar Cholangiocarcinoma
Interventions: Drug: Photosensitizer; Procedure: Radiofrequency ablation (RFA)
Sponsors: University of Leipzig; Zentrum für Klinische Studien Leipzig
Recruiting
Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Posted: August 25th, 2022, 2:00pm GMT

Conditions: Resectable Intrahepatic Cholangiocarcinoma; Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8; Stage I Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Drug: Infigratinib Phosphate; Drug: Nab-paclitaxel
Sponsors: Emory University; National Cancer Institute (NCI)
Not yet recruiting
Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Posted: August 22nd, 2022, 2:00pm GMT

Conditions: Cholangiocarcinoma; Liver Cancer
Interventions: Drug: Infigratinib; Drug: Atezolizumab; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; Helsinn Healthcare
Not yet recruiting
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

Posted: August 16th, 2022, 2:00pm GMT

Conditions: Advanced Solid Tumor; BRAF V600 Mutation
Intervention: Drug: ABM-1310
Sponsor: ABM Therapeutics Shanghai Company Limited
Recruiting
Ablation of Hepatocellular Carcinoma: a Nationwide Study

Posted: August 12th, 2022, 2:00am GMT

Conditions: Hepatocellular Carcinoma; Ablation; Hepatitis C
Interventions: Procedure: Ablation therapy
Sponsors: Rigshospitalet, Denmark
Completed
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers

Posted: August 11th, 2022, 2:00pm GMT

Conditions: Hepatobiliary Cancer; Pancreatic Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Ampullary Cancer; Pancreatic Carcinoma
Intervention: Diagnostic Test: ctDNA Blood Collection
Sponsor: University of California, Irvine
Recruiting
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Posted: July 18th, 2022, 2:00pm GMT

Conditions: Pleural Effusion, Malignant; Ascites, Malignant; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Renal; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Neuroendocrine; Carcinoma, Thymic; Carcinoma, Pancreatic; Carcinoma Breast; Carcinoma, Ovarian; Carcinoma Bladder; Carcinoma of Unknown Primary; Carcinoma of the Head and Neck; Carcinoma of the Oropharynx; Carcinoma of the Larynx; Carcinoma of the Bladder; Carcinoma of Esophagus; Carcinoma of the Nasopharynx; Carcinoma of the Penis; Carcinoma of the Cervix; Carcinoma of the Anus; Carcinoma of the Vulva; Carcinoma of the Appendix; Carcinoma of the Oral Cavity; Cholangiocarcinoma; Melanoma; Mesothelioma; Pancreatic Cancer
Intervention:
Sponsors: Travera Inc; xCures
Recruiting
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Posted: July 11th, 2022, 2:00pm GMT

Conditions: Mesothelioma; Mesotheliomas Pleural; Mesothelioma, Malignant; Mesothelioma Peritoneum; Ovarian Cancer; Ovarian Serous Adenocarcinoma; Pancreatic Cancer; Pancreatic Adenocarcinoma; Colorectal Cancer; Triple Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Ovarian Adenocarcinoma; Pancreatic Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Cholangiocarcinoma; Non Small Cell Lung Cancer
Interventions: Biological: TC-510; Drug: Fludarabine; Drug: Cyclophosphamide
Sponsor: TCR2 Therapeutics
Recruiting
Effect of Sarcopenia on Hepatocellular Carcinoma(HCC) After Systemic Therapies

Posted: July 7th, 2022, 2:00am GMT

Conditions: Hepatocellular Carcinoma; Sarcopenia
Interventions: Diagnostic Test: Diagnostic Test: gait speed; ct scan; grip strength and chair stand test
Sponsors: First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Zhejiang Chinese Medical University; Eastern Hepatobiliary Surgery Hospital; Qilu Hospital of Shandong University
Enrolling by invitation
Effect of Sarcopenia on HCC After Lenvatinib and Anti-PD-1 Treatment

Posted: July 5th, 2022, 2:00am GMT

Conditions: Liver Cancer; Sarcopenia
Interventions: Diagnostic Test: gait speed; ct scan; grip strength and chair stand test
Sponsors: First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Zhejiang Chinese Medical University; Eastern Hepatobiliary Surgery Hospital; Qilu Hospital of Shandong University
Enrolling by invitation
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Posted: June 27th, 2022, 2:00pm GMT

Conditions: Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Esophageal Cancer; Melanoma (Skin); Soft Tissue Sarcoma; Head and Neck Squamous Cell Carcinoma; Cholangiocarcinoma
Interventions: Drug: [Ga-68]-PNT6555; Drug: [Lu-177]-PNT6555
Sponsors: POINT Biopharma
Active, not recruiting
PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma

Posted: June 24th, 2022, 2:00pm GMT

Condition: Perihilar Cholangiocarcinoma
Intervention: Drug: PD-1antibody plus GEMOX
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting
The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Nab-paclitaxel Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

Posted: June 16th, 2022, 2:00pm GMT

Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Induction Chemotherapy Triplet Therapy; Radiation: Concurrent Y-90 treatment; Drug: Consolidation Doublet Therapy:
Sponsors: Inova Health Care Services
Not yet recruiting
Treatment of ARB202 Advanced Gastrointestinal Cancer Patients

Posted: June 9th, 2022, 2:00am GMT

Conditions: Gastrointestinal Cancer; Cholangiocarcinoma; Liver Cancer; Colorectal Adenocarcinoma; Pancreatic Cancer; Gastric Cancer
Interventions: Drug: ARB202
Sponsors: Arbele Pty Ltd
Recruiting
HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma

Posted: June 2nd, 2022, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Intervention: Drug: HAIC Combined with Tislelizumab and Apatinib
Sponsor: Binkui Li
Recruiting
Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment

Posted: April 14th, 2022, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Perflutren Protein-Type A Microspheres; Procedure: Contrast-Enhanced Ultrasound
Sponsor: Thomas Jefferson University
Recruiting
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Posted: April 13th, 2022, 2:00pm GMT

Conditions: Solid Tumors
Interventions: Drug: Bemarituzumab
Sponsors: Amgen
Recruiting
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors

Posted: April 6th, 2022, 2:00am GMT

Conditions: CNS Cancer; Head and Neck Cancer; GI Cancer; Gynecologic Cancer; Prostate Cancer; Thoracic Cancer; Breast Cancer
Interventions: Radiation: Pencil Beam Scanning Proton Therapy
Sponsors: The New York Proton Center
Recruiting
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

Posted: March 23rd, 2022, 2:00pm GMT

Conditions: Gynecologic Cancer; Colorectal Cancer; Pancreatic Cancer; Non-small Cell Lung Cancer; Cholangiocarcinoma; Ovarian Cancer; Ovary Neoplasm; Squamous Cell Lung Cancer; Adenocarcinoma of Lung; Adenosquamous Cell Lung Cancer
Intervention: Biological: Neoantigen specific TCR-T cell drug product
Sponsor: Alaunos Therapeutics
Recruiting
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer

Posted: March 23rd, 2022, 2:00pm GMT

Conditions: Primary Liver Cancer; Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Combined Hepatocellular-cholangiocarcinoma
Interventions: Other: Observation
Sponsors: Geneplus-Beijing Co. Ltd.; Eastern Hepatobiliary Surgery Hospital
Recruiting
M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma

Posted: March 18th, 2022, 2:00pm GMT

Conditions: Metastatic Colorectal Cancer (Mcrc); Intrahepatic Cholangiocarcinoma (Icc); Colorectal Cancer; Colorectal Neoplasms; Cholangiocarcinoma; Intrahepatic Bile Duct Cancer; Bile Duct Cancer; Bile Duct Neoplasms
Interventions: Drug: Floxuridine; Drug: 5-Fluorouracil; Drug: Irinotecan; Device: Intera 3000 Hepatic Artery Infusion Pump (HAIP); Drug: Oxaliplatin; Drug: Leucovorin; Drug: M9241; Drug: Gemcitabine; Drug: Dexamethasone
Sponsors: National Cancer Institute (NCI)
Recruiting

1 2 3

← Trial - Bile Duct Cancer Google - Rare Brain Tumor →

Rare Cancer News & Clinical Trials » Trial - Cholangiocarcinoma

Feeds

Trial - Cholangiocarcinoma (100 unread)

Posted: November 24th, 2023, 3:00am GMT

Posted: November 20th, 2023, 3:00am GMT

Posted: November 16th, 2023, 3:00am GMT

Posted: November 10th, 2023, 3:00am GMT

Posted: November 9th, 2023, 3:00am GMT

Posted: November 3rd, 2023, 2:00am GMT

Posted: October 31st, 2023, 2:00am GMT

Posted: October 30th, 2023, 2:00am GMT

Posted: October 26th, 2023, 2:00am GMT

Posted: October 24th, 2023, 2:00am GMT

Posted: October 20th, 2023, 2:00am GMT

Posted: October 13th, 2023, 2:00am GMT

Posted: October 13th, 2023, 2:00am GMT

Posted: October 10th, 2023, 2:00am GMT

Posted: September 28th, 2023, 2:00am GMT

Posted: September 27th, 2023, 2:00am GMT

Posted: September 22nd, 2023, 2:00pm GMT

Posted: September 21st, 2023, 2:00pm GMT

Posted: September 21st, 2023, 2:00pm GMT

Posted: September 21st, 2023, 2:00pm GMT

Posted: September 14th, 2023, 2:00pm GMT

Posted: September 12th, 2023, 2:00pm GMT

Posted: September 8th, 2023, 2:00pm GMT

Posted: August 30th, 2023, 2:00pm GMT

Posted: August 25th, 2023, 2:00pm GMT

Posted: August 15th, 2023, 2:00pm GMT

Posted: August 14th, 2023, 2:00pm GMT

Posted: August 7th, 2023, 2:00pm GMT

Posted: August 2nd, 2023, 2:00pm GMT

Posted: August 1st, 2023, 2:00pm GMT

Posted: July 24th, 2023, 2:00pm GMT

Posted: July 24th, 2023, 2:00pm GMT

Posted: July 17th, 2023, 2:00pm GMT

Posted: July 5th, 2023, 2:00am GMT

Posted: June 27th, 2023, 2:00pm GMT

Posted: June 27th, 2023, 2:00pm GMT

Posted: June 22nd, 2023, 2:00pm GMT

Posted: June 22nd, 2023, 2:00pm GMT

Posted: June 9th, 2023, 2:00pm GMT

Posted: May 25th, 2023, 2:00pm GMT

Posted: May 25th, 2023, 2:00pm GMT

Posted: May 24th, 2023, 2:00pm GMT

Posted: May 24th, 2023, 2:00pm GMT

Posted: May 15th, 2023, 2:00pm GMT

Posted: May 9th, 2023, 2:00pm GMT

Posted: May 8th, 2023, 2:00pm GMT

Posted: April 28th, 2023, 2:00pm GMT

Posted: April 21st, 2023, 2:00pm GMT

Posted: April 17th, 2023, 2:00pm GMT

Posted: April 10th, 2023, 2:00pm GMT

Posted: March 30th, 2023, 2:00pm GMT

Posted: March 29th, 2023, 2:00pm GMT

Posted: March 23rd, 2023, 2:00am GMT

Posted: March 16th, 2023, 2:00pm GMT

Posted: March 9th, 2023, 3:00pm GMT

Posted: March 1st, 2023, 3:00pm GMT

Posted: March 1st, 2023, 3:00pm GMT

Posted: February 24th, 2023, 3:00pm GMT

Posted: February 21st, 2023, 3:00pm GMT

Posted: February 17th, 2023, 3:00pm GMT

Posted: February 14th, 2023, 3:00pm GMT

Posted: February 13th, 2023, 3:00pm GMT

Posted: February 10th, 2023, 3:00pm GMT

Posted: February 8th, 2023, 3:00pm GMT

Posted: February 6th, 2023, 3:00pm GMT

Posted: January 31st, 2023, 3:00pm GMT

Posted: January 12th, 2023, 3:00pm GMT

Posted: January 10th, 2023, 3:00pm GMT

Posted: December 19th, 2022, 3:00pm GMT

Posted: December 8th, 2022, 3:00pm GMT

Posted: November 14th, 2022, 3:00pm GMT

Posted: November 1st, 2022, 2:00am GMT

Posted: October 26th, 2022, 2:00pm GMT